STAFFORD, Texas, May  22, 2026  (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (&#34;Greenwich&#34; or the &#34;Company&#34;), a clinical-stage biopharmaceutical company focused on its Phase III clinical

GLSI

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

GLSI faces Nasdaq non-compliance notification but remains listed

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>STAFFORD, Texas, May  22, 2026  (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (&amp;#34;Greenwich&amp;#34; or the &amp;#34;Company&amp;#34;), a clinical-stage biopharmaceutical company focused on its Phase III clinical</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Greenwich LifeSciences (GLSI) has received a Nasdaq non-compliance notice due to its failure to file the quarterly report for Q1 2026. While this does not impact its current listing status, investors should monitor any future compliance actions that could affect stock performance.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>GLSI received a notice of non-compliance from Nasdaq.</li><li>Company has not filed its March 31, 2026, 10-Q report.</li><li>No immediate effect on GLSI&#039;s listing or trading activities.</li><li>GLSI is currently conducting Phase III clinical trial for GLSI-100.</li><li>Focus remains on developing immunotherapy for breast cancer recurrences.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Nasdaq, Inc. (NDAQ)</strong>: Monitor Nasdaq developments for compliance-related impacts.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This article fits within Corporate Developments, highlighting important compliance issues that could influence GLSI’s stock stability and investor trust in the company&#039;s financial management.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Potential for increased volatility if the non-compliance issue isn&#039;t resolved quickly.</li><li>Updates on Phase III trial results may move GLSI&#039;s stock price significantly.</li><li>Market reactions could intensify around the filing of the 10-Q.</li><li>Investor sentiment may shift if further compliance issues arise.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>GLSI is currently in a Phase III trial for GLSI-100.</li><li>Received Nasdaq non-compliance notice on May 20, 2026.</li><li>Last filed 10-Q was due by March 31, 2026.</li><li>Currently retains its listing on the Nasdaq Capital Market.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider a cautious hold on GLSI given compliance risks and ongoing clinical developments.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify"><b>STAFFORD, Texas, May  22, 2026  (GLOBE NEWSWIRE) -- </b>Greenwich LifeSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/GLSI">GLSI</a>) (&#34;Greenwich&#34; or the &#34;Company&#34;), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on May 20, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it has not yet filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026, the Company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The notice has no immediate effect on the listing or trading of the Company's common stock, which continues to trade on the Nasdaq Capital Market under the symbol &#34;GLSI.&#34;</p>  <p><b>About Greenwich LifeSciences, Inc.</b></p>  <p align="justify">Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company&#39;s website at <a href="https://www.globenewswire.com/Tracker?data=cXCnP48nCBakgrX54wHvcDsLv840rl8_X6bbWaOwoM8IU3CDH7pAw8NFEyWNWcb6h5j_Kr-kQevAc9fDvM1jt-w13vA1MkIVdb9HS-kvJP3uWX7SbRQW8A2YehVyLABm" rel="nofollow" target="_blank">www.greenwichlifesciences.com</a> and follow the Company&#39;s Twitter at <a href="https://www.globenewswire.com/Tracker?data=yHX9P5Op8xGRovsD-X99mCgeF3XzIZokPbKePmH48iRVwSiQYn3lYQLQlK4amlqaOe9hYGiTRUmOzAGIx1XpmO-cEAdOjS9wNgMG80VNt--m-YxYkM29G0826Cyke00t" rel="nofollow" target="_blank">https://twitter.com/GreenwichLS</a>.</p>  <p align="justify"><b>Forward-Looking Statement Disclaimer</b></p>  <p align="justify">Statements in this press release contain &#34;forward-looking statements&#34; that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as &#34;anticipate,&#34; &#34;believe,&#34; &#34;contemplate,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;seek,&#34; &#34;may,&#34; &#34;might,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;target,&#34; &#34;aim,&#34; &#34;should,&#34; &#34;will,&#34; &#34;would,&#34; or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.&#39;s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled &#34;Risk Factors&#34; in Greenwich LifeSciences&#39; Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.</p>  <p align="justify"><b>Company Contact</b></p>  <p>Snehal Patel<br></br>Investor Relations<br></br>Office: (832) 819-3232<br></br>Email: <a href="https://www.globenewswire.com/Tracker?data=bMUy_GyEeIvuS0UVatkcSo_Ai1ef4klHjexfG-jG7joEraSLEcQneF2PDrRz-Kmrfk3VsgnGJZ6eAyH2hxvuB_X8nw7DJKSBkkxZ6GdW3HkR71fBOt771GwjaCBtBwIw" rel="nofollow" target="_blank">info@greenwichlifesciences.com</a></p>  <p align="justify"><b>Investor &amp; Public Relations Contact for Greenwich LifeSciences</b></p>  <p>Dave Gentry<br></br>RedChip Companies Inc.<br></br>Office: 1-800-RED CHIP (733 2447)<br></br>Email: <a href="https://www.globenewswire.com/Tracker?data=u71pm5DAaGlBHW_Sm90EKdNDengjMehfAkCVe_xuL9SOz5MBLdAN0IyZzxgDZrPbwlHtFE2UW8DlDOUap4UfErtygsWPjl4mIpbqBCkfqAY=" rel="nofollow" target="_blank">dave@redchip.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcyNTAwMiM3NjE2NjgyIzUwMDExMzg3NQ=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MDAzODFkZTYtMDUzMC00ZWNmLTllYzYtNzhlMjhmODUwNTM3LTUwMDExMzg3NS0yMDI2LTA1LTIyLWVu/tiny/Greenwich-LifeSciences-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/e0bfd967-b05f-43d2-91b4-d2a5d551df99"><img src="https://ml.globenewswire.com/media/e0bfd967-b05f-43d2-91b4-d2a5d551df99/small/logo-edited-jpg.jpg" border="0" width="150" height="62" alt="Primary Logo"></img></a></p>

Greenwich LifeSciences (GLSI) has received a Nasdaq non-compliance notice due to its failure to file the quarterly report for Q1 2026. While this does not impact its current listing status, investors should monitor any future compliance actions that could affect stock performance.

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News